Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia.
Schizophrenia is a mental disorder characterized by a series of positive, negative or cognitive symptoms but with also the particularity of exhibiting a high rate of co-morbid use of drugs of abuse. While more than 80% of schizophrenics are smokers, the second most consumed drug is alcohol, with dramatic consequences on frequency and intensity of psychotic episodes and on life expectancy. Here we investigated the impact of light alcohol intake during adolescence on the subsequent occurrence of alcohol addiction-like behavior in neonatal ventral hippocampal lesion (NVHL) rats, a neurodevelopmental model of schizophrenia. Our findings demonstrated an increased liability to addictive behaviors in adult NVHL rats after voluntary alcohol intake during adolescence. NVHL rats displayed several signs of alcohol use disorder such as a loss of control over alcohol intake and high motivation to consume alcohol, associated with a higher resistance to extinction. In addition, once NVHL rats relapsed, they maintained higher drinking levels than controls. We finally showed that the anti-addictive drug naltrexone is efficient in reducing excessive alcohol intake in NVHL rats. Our results are in accordance with epidemiological studies underlying the particular vulnerability to alcohol addiction after adolescent exposure to alcohol and highlight the fact that schizophrenic subjects may be particularly at risk even after light alcohol consumption. Based on these results, it seems particularly relevant to prevent early onset of alcohol use in at-risk subjects and thus to reduce the incidence of co-morbid alcohol abuse in psychotic patients.
Groupe de Recherche sur l'Alcool et les Pharmacodépendances-INSERM ERI 24, UFR de Pharmacie, SFR CAP Santé, Université de Picardie Jules Verne, France.
Jérôme
J
Jeanblanc
Kevin
K
Balguerie
Fabien
F
Coune
Rémi
R
Legastelois
Virginie
V
Jeanblanc
Mickaël
M
Naassila
D000428:Alcohol Drinking / Q000009:adverse effects* / Q000517:prevention & control; D000437:Alcoholism / Q000209:etiology* / Q000517:prevention & control; D000818:Animals; D000831:Animals, Newborn; D002492:Central Nervous System Depressants / Q000494:pharmacology; D003216:Conditioning, Operant; D004195:Disease Models, Animal; D058999:Drug-Seeking Behavior / Q000187:drug effects; D000431:Ethanol / Q000494:pharmacology; D006624:Hippocampus / Q000502:physiology; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D017207:Rats, Sprague-Dawley; D012559:Schizophrenia / Q000150:complications*
D002492:Central Nervous System Depressants; D009292:Narcotic Antagonists; D000431:Ethanol; D009271:Naltrexone
Adolescence; alcohol use disorders; animal model; dual diagnosis; relapse; schizophrenia